1. Home
  2. CERO vs DGLY Comparison

CERO vs DGLY Comparison

Compare CERO & DGLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CERO
  • DGLY
  • Stock Information
  • Founded
  • CERO 2017
  • DGLY 2004
  • Country
  • CERO United States
  • DGLY United States
  • Employees
  • CERO N/A
  • DGLY N/A
  • Industry
  • CERO
  • DGLY Radio And Television Broadcasting And Communications Equipment
  • Sector
  • CERO
  • DGLY Technology
  • Exchange
  • CERO Nasdaq
  • DGLY Nasdaq
  • Market Cap
  • CERO 3.5M
  • DGLY 3.9M
  • IPO Year
  • CERO N/A
  • DGLY N/A
  • Fundamental
  • Price
  • CERO $7.50
  • DGLY $1.98
  • Analyst Decision
  • CERO Strong Buy
  • DGLY
  • Analyst Count
  • CERO 2
  • DGLY 0
  • Target Price
  • CERO $45.00
  • DGLY N/A
  • AVG Volume (30 Days)
  • CERO 95.7K
  • DGLY 82.6K
  • Earning Date
  • CERO 08-13-2025
  • DGLY 08-15-2025
  • Dividend Yield
  • CERO N/A
  • DGLY N/A
  • EPS Growth
  • CERO N/A
  • DGLY N/A
  • EPS
  • CERO N/A
  • DGLY N/A
  • Revenue
  • CERO N/A
  • DGLY $18,596,715.00
  • Revenue This Year
  • CERO N/A
  • DGLY N/A
  • Revenue Next Year
  • CERO N/A
  • DGLY N/A
  • P/E Ratio
  • CERO N/A
  • DGLY N/A
  • Revenue Growth
  • CERO N/A
  • DGLY N/A
  • 52 Week Low
  • CERO $6.71
  • DGLY $1.91
  • 52 Week High
  • CERO $895.40
  • DGLY $203.77
  • Technical
  • Relative Strength Index (RSI)
  • CERO 40.75
  • DGLY 26.10
  • Support Level
  • CERO $7.27
  • DGLY $1.93
  • Resistance Level
  • CERO $8.83
  • DGLY $2.11
  • Average True Range (ATR)
  • CERO 0.43
  • DGLY 0.12
  • MACD
  • CERO -0.06
  • DGLY 0.46
  • Stochastic Oscillator
  • CERO 13.14
  • DGLY 17.07

About CERO CERo Therapeutics Holdings Inc. Common Stock

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.

About DGLY Digital Ally Inc.

Digital Ally Inc produces digital video imaging and storage products for use in law enforcement, security, and commercial applications. Its products are an in-car digital video/audio recorder contained in a rear-view mirror for use in law enforcement and commercial fleets. It can integrate electronic, radio, computer, and multi-media technologies to create solutions to address needs in a variety of other industries and markets, including mass transit, school buses, taxicab, and military. The company sells its products directly to law enforcement agencies, security organizations, and consumer and commercial fleet operators both domestically and internationally through third-party distributors. Its segments include Video Solutions, Revenue Cycle Management, and Entertainment.

Share on Social Networks: